ProCE Banner Activity

Clinical Data on TROP2-Targeting ADCs in Breast, Urothelial, and Lung Cancers


Download this slideset from a live CCO symposium for nurses to get up to date on the latest clinical data for the TROP2 ADCs sacituzumab govitecan and datopotamab deruxtecan across multiple tumor types. 

Released: April 28, 2023



Elise Hitron

Elise Hitron, MSN, FNP-C

Nurse Practitioner
Phase I Clinical Trials at Winship Cancer Institute
Atlanta, Georgia

Srigowri Kota

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN

Nurse Practitioner
Department of Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Neelima Vidula

Neelima Vidula, MD

Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Department of Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.